The Experts below are selected from a list of 7257 Experts worldwide ranked by ideXlab platform
Mrinal M. Patnaik - One of the best experts on this subject based on the ideXlab platform.
-
Nonhepatosplenic extramedullary manifestations of Chronic Myelomonocytic Leukemia: clinical, molecular and prognostic correlates.
Leukemia & lymphoma, 2018Co-Authors: Katherine P. Hoversten, Rangit Vallapureddy, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Mrinal M. PatnaikAbstract:Chronic Myelomonocytic Leukemia (CMML) is an aggressive hematological malignancy with overlapping myeloproliferative and myelodysplastic features and an inherent risk for leukemic transformation [1...
-
flow cytometry based monocyte subset analysis accurately distinguishes Chronic Myelomonocytic Leukemia from myeloproliferative neoplasms with associated monocytosis
Blood Cancer Journal, 2017Co-Authors: Mrinal M. Patnaik, Eric Solary, Rangit Vallapureddy, Terra L. Lasho, Rhett P. Ketterling, Naseema Gangat, A Tefferi, Michael Timm, Min Shi, Kaaren K ReichardAbstract:Flow cytometry based monocyte subset analysis accurately distinguishes Chronic Myelomonocytic Leukemia from myeloproliferative neoplasms with associated monocytosis
-
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with Chronic Myelomonocytic Leukemia
Leukemia & lymphoma, 2016Co-Authors: Mohammad Faizan Zahid, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Daniela Barraco, Mrinal M. PatnaikAbstract:Chronic Myelomonocytic Leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms that has an inheren...
-
Number and type of TET2 mutations in Chronic Myelomonocytic Leukemia and their clinical relevance
Blood cancer journal, 2016Co-Authors: Mrinal M. Patnaik, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Mohammad Faizan Zahid, Keith D. Robertson, Ayalew TefferiAbstract:Number and type of TET2 mutations in Chronic Myelomonocytic Leukemia and their clinical relevance
-
Hypomethylating agents are effective in shrinking splenomegaly in patients with Chronic Myelomonocytic Leukemia
Leukemia & lymphoma, 2016Co-Authors: Salih Subari, Mrinal M. Patnaik, Dima Alfakara, Darci Zblewski, Chris Hook, Shahrukh K. Hashmi, William J. Hogan, Mark R. Litzow, Aref Al-kaliAbstract:Chronic Myelomonocytic Leukemia (CMML) is an heterogenous hematologic malignancy with mixed myelodysplastic and myeloproliferative features. It is characterized by peripheral blood monocytosis and ...
Nathalie Droin - One of the best experts on this subject based on the ideXlab platform.
-
setbp1 mutations in 658 patients with myelodysplastic syndromes Chronic Myelomonocytic Leukemia and secondary acute myeloid Leukemias
Leukemia, 2013Co-Authors: Olivier Kosmider, Raphael Itzykson, Nathalie Droin, Frederik DammAbstract:SETBP1 mutations in 658 patients with myelodysplastic syndromes, Chronic Myelomonocytic Leukemia and secondary acute myeloid Leukemias
-
Current insights in the cellular and molecular biology of Chronic Myelomonocytic Leukemia
International Journal of Hematologic Oncology, 2012Co-Authors: Raphael Itzykson, Nathalie Droin, Eric SolaryAbstract:SUMMARY Chronic Myelomonocytic Leukemia is a rare clonal myeloid disorder most often seen in the elderly that remains a virtually incurable disease. Chronic Myelomonocytic Leukemia has long been considered as a myelodysplastic syndrome by diagnostic classifications, but recent insights in the cellular and molecular biology of the disease has refined its identity. The malignant clone was shown to generate myeloid-derived suppressive cells that may contribute to disease expansion, whereas the role of progenitor hypersensitivity to granulomonocyte colony-stimulating factor probably defines two distinct subgroups. At least one gene mutation can now be identified in almost all the patients. The most frequently mutated genes are TET2, SRSF2 and ASXL1, with a frequent combination of mutations in the first two genes, whereas ASXL1 mutations define a poor prognostic subgroup of patients. A number of additional mutations have been identified that confer to the disease its phenotype specificity; for example, mutatio...
Terra L. Lasho - One of the best experts on this subject based on the ideXlab platform.
-
Nonhepatosplenic extramedullary manifestations of Chronic Myelomonocytic Leukemia: clinical, molecular and prognostic correlates.
Leukemia & lymphoma, 2018Co-Authors: Katherine P. Hoversten, Rangit Vallapureddy, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Mrinal M. PatnaikAbstract:Chronic Myelomonocytic Leukemia (CMML) is an aggressive hematological malignancy with overlapping myeloproliferative and myelodysplastic features and an inherent risk for leukemic transformation [1...
-
flow cytometry based monocyte subset analysis accurately distinguishes Chronic Myelomonocytic Leukemia from myeloproliferative neoplasms with associated monocytosis
Blood Cancer Journal, 2017Co-Authors: Mrinal M. Patnaik, Eric Solary, Rangit Vallapureddy, Terra L. Lasho, Rhett P. Ketterling, Naseema Gangat, A Tefferi, Michael Timm, Min Shi, Kaaren K ReichardAbstract:Flow cytometry based monocyte subset analysis accurately distinguishes Chronic Myelomonocytic Leukemia from myeloproliferative neoplasms with associated monocytosis
-
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with Chronic Myelomonocytic Leukemia
Leukemia & lymphoma, 2016Co-Authors: Mohammad Faizan Zahid, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Daniela Barraco, Mrinal M. PatnaikAbstract:Chronic Myelomonocytic Leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms that has an inheren...
-
Number and type of TET2 mutations in Chronic Myelomonocytic Leukemia and their clinical relevance
Blood cancer journal, 2016Co-Authors: Mrinal M. Patnaik, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Mohammad Faizan Zahid, Keith D. Robertson, Ayalew TefferiAbstract:Number and type of TET2 mutations in Chronic Myelomonocytic Leukemia and their clinical relevance
-
Chronic Myelomonocytic Leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.
Blood cancer journal, 2015Co-Authors: Mrinal M. Patnaik, Francesco Onida, Terra L. Lasho, Christy Finke, Olivier Kosmider, Emnet A. Wassie, Eric Padron, Raphael Itzykson, C A Hanson, Rhett P. KetterlingAbstract:Chronic Myelomonocytic Leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
Ayalew Tefferi - One of the best experts on this subject based on the ideXlab platform.
-
Nonhepatosplenic extramedullary manifestations of Chronic Myelomonocytic Leukemia: clinical, molecular and prognostic correlates.
Leukemia & lymphoma, 2018Co-Authors: Katherine P. Hoversten, Rangit Vallapureddy, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Mrinal M. PatnaikAbstract:Chronic Myelomonocytic Leukemia (CMML) is an aggressive hematological malignancy with overlapping myeloproliferative and myelodysplastic features and an inherent risk for leukemic transformation [1...
-
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with Chronic Myelomonocytic Leukemia
Leukemia & lymphoma, 2016Co-Authors: Mohammad Faizan Zahid, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Daniela Barraco, Mrinal M. PatnaikAbstract:Chronic Myelomonocytic Leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms that has an inheren...
-
Number and type of TET2 mutations in Chronic Myelomonocytic Leukemia and their clinical relevance
Blood cancer journal, 2016Co-Authors: Mrinal M. Patnaik, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Mohammad Faizan Zahid, Keith D. Robertson, Ayalew TefferiAbstract:Number and type of TET2 mutations in Chronic Myelomonocytic Leukemia and their clinical relevance
-
Chronic Myelomonocytic Leukemia: Focus on Clinical Practice
Mayo Clinic proceedings, 2016Co-Authors: Mrinal M. Patnaik, Ayalew TefferiAbstract:Chronic Myelomonocytic Leukemia (CMML) is a clonal stem cell disorder with features that overlap those of myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms (MPNs). Chronic Myelomonocytic Leukemia often results in peripheral blood monocytosis and has an inherent tendency to transform to acute myeloid Leukemia. Clonal cytogenetic changes are seen in approximately 30% of patients, and molecular abnormalities are seen in more than 90%. Gene mutations involving TET2 (∼60%), SRSF2 (∼50%), ASXL1 (∼40%), and RAS (∼30%) are frequent, with nonsense and frameshift ASXL1 mutations being the only mutations identified thus far to have an independent negative prognostic effect on overall survival. Contemporary molecularly integrated prognostic models (inclusive of ASXL1 mutations) include the Molecular Mayo Model and the Groupe Francais des Myelodysplasies model. Given the lack of formal treatment and response criteria, management of CMML is often extrapolated from MDS and MPN, with allogeneic stem cell transplant being the only curative option. Hydroxyurea and other cytoreductive agents have been used to control MPN-like features, while epigenetic modifiers such as hypomethylating agents have been used for MDS-like features. Given the relatively poor response to these agents and the inherent risks associated with hematopoietic stem cell transplant, newer drugs exploiting molecular and epigenetic abnormalities in CMML are being developed. The creation of CMML-specific response criteria is a much needed step in order to improve clinical outcomes.
-
concomitant analysis of ezh2 and asxl1 mutations in myelofibrosis Chronic Myelomonocytic Leukemia and blast phase myeloproliferative neoplasms
Leukemia, 2011Co-Authors: Omar Abdelwahab, Terra L. Lasho, Animesh Pardanani, Ross L Levine, Jay P Patel, Martha Wadleigh, Adriana Heguy, M Beran, D G Gilliland, Ayalew TefferiAbstract:Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, Chronic Myelomonocytic Leukemia and blast-phase myeloproliferative neoplasms
Rhett P. Ketterling - One of the best experts on this subject based on the ideXlab platform.
-
Nonhepatosplenic extramedullary manifestations of Chronic Myelomonocytic Leukemia: clinical, molecular and prognostic correlates.
Leukemia & lymphoma, 2018Co-Authors: Katherine P. Hoversten, Rangit Vallapureddy, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Mrinal M. PatnaikAbstract:Chronic Myelomonocytic Leukemia (CMML) is an aggressive hematological malignancy with overlapping myeloproliferative and myelodysplastic features and an inherent risk for leukemic transformation [1...
-
flow cytometry based monocyte subset analysis accurately distinguishes Chronic Myelomonocytic Leukemia from myeloproliferative neoplasms with associated monocytosis
Blood Cancer Journal, 2017Co-Authors: Mrinal M. Patnaik, Eric Solary, Rangit Vallapureddy, Terra L. Lasho, Rhett P. Ketterling, Naseema Gangat, A Tefferi, Michael Timm, Min Shi, Kaaren K ReichardAbstract:Flow cytometry based monocyte subset analysis accurately distinguishes Chronic Myelomonocytic Leukemia from myeloproliferative neoplasms with associated monocytosis
-
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with Chronic Myelomonocytic Leukemia
Leukemia & lymphoma, 2016Co-Authors: Mohammad Faizan Zahid, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Daniela Barraco, Mrinal M. PatnaikAbstract:Chronic Myelomonocytic Leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms that has an inheren...
-
Number and type of TET2 mutations in Chronic Myelomonocytic Leukemia and their clinical relevance
Blood cancer journal, 2016Co-Authors: Mrinal M. Patnaik, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Mohammad Faizan Zahid, Keith D. Robertson, Ayalew TefferiAbstract:Number and type of TET2 mutations in Chronic Myelomonocytic Leukemia and their clinical relevance
-
Chronic Myelomonocytic Leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.
Blood cancer journal, 2015Co-Authors: Mrinal M. Patnaik, Francesco Onida, Terra L. Lasho, Christy Finke, Olivier Kosmider, Emnet A. Wassie, Eric Padron, Raphael Itzykson, C A Hanson, Rhett P. KetterlingAbstract:Chronic Myelomonocytic Leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome